The Food and Drug Administration has been approving new cancer treatments at a rapid pace. Here are the latest arrivals:

  • Blenrep (belantamab mafodotin) for multiple myeloma
  • Inqovi (decitabine/cedazuridine) for myelodysplastic syndrome
  • Monjuvi (tafasitamab) for diffuse large B-cell lymphoma
  • Mylotarg (gemtuzumab ozogamicin) for acute myeloid leukemia
  • Phesgo (pertuzumab/trastuzumab/hyaluronidase) for HER2-positive breast cancer
  • Qinlock (ripretinib) for advanced gastrointestinal stromal tumor
  • Tecartus (brexucabtagene autoleucel) CAR-T therapy for mantle cell lymphoma
  • Zepzelca (lurbinectedin) for small cell lung cancer